5Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010 : a systematic review and analysis [J] . Lancet, 2013, 382 ( 991 ) : 1329-1340.
6Anderson JL, Halperin JL, Albert NM, et al. Management of patients with peripheral artery disease ( compilation of 2005 and 2011 ACCF/ AHA guideline recommendations ) : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [ J ] . Circulation, 2013, 127 ( 13 ) : 1425- 1443.
7Guo X, Xue G, Huang X, et al. Outcomes of endovascular treatment for patients with TASC IID femoropopliteal occlusive disease : a single center study [ J ] . BMC Cardiovasc Disord, 2015, 15 ( 1 ) : 44.
8Wu X, Lu Q. Expression and significance of c -SMA and PCNA in the vascular adventitia of balloon-injured rat aorta [ J ] . Exp Ther Med, 2013, 5 ( 6 ) : 1671-1676.
9Filippatos G, Parissis JT, Adamopoulos S, et al. Chemokines in cardiovascular remodeling : clinical and therapeutic implications[J]. Curr Mol Med, 2003, 3 ( 2 ) : 139-147.
10Maeda DY, Peck AM, Schuler AD, et al, Discovery of 2- [ 5- ( 4-Fluorophenylcarbamoyl ) pyridin-2-ylsulfanylmethyl] phenylboronic acid ( SX-517 ) : noncompetitive boronic acid antagonist of CXCR1 and CXCR2 [ J ]. J Med Chem. 2014, 57 ( 20 ): 8378-8397.
